Longeveron (LGVN)

Executive Summary

Longeveron is a clinical-stage biotechnology company focused on developing cellular therapies for aging-related and life-threatening conditions, with a lead product candidate, Lomecel-B (allogeneic mesenchymal stem cells). The company's pipeline targets mild Alzheimer's disease, aging frailty, hypoplastic left heart syndrome (HLHS), and ARDS. Most advanced programs include a completed Phase 2 trial in mild Alzheimer's (NCT05233774) and a Phase 2 trial in aging frailty (NCT03169231), both completed, with data yet to yield regulatory filings. A key ongoing study is the Phase 2 ELPIS trial for HLHS (NCT04925024), expected to complete in August 2026. With a market cap of ~$25M, Longeveron is early-stage with no approved products, relying on successful clinical outcomes and partnerships. The company's technology aims to improve healthspan by enhancing the body's regenerative capacity, but remains unproven in pivotal trials.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 HLHS trial (ELPIS) top-line results40% success
• TBDRegulatory feedback or path forward for aging frailty program30% success
• TBDPartnering or licensing deal for Lomecel-B20% success